Skip to main content

Table 1 Demographic characteristics of the study population

From: CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe

 

N=185

 

Characteristics

Males, n=60

Females n=125

P value

Age (years)

40.16667 (9.141)

38.336 (8.065)

0.1683

Weight (kg)

61.51667 ( 10.058)

57.92 (11.291)

0.0372

Height (m)

1.718644 (0.089)

1.607258 (0 .084)

<0.001

Duration on EFV (months)

6.941667 (9.967)

10.30456 (12.272)

0.0661

CNS Toxicity,

   

Yes

26 [32.91]

53 [67.09]

 

No

34 [32.08]

72 [67.92]

0.904

Log EFV concentration

1.382 (1.274)

1.632 ( 1.069)

0.1638

Genetic polymorphisms

   

CYP2B6*6 ,

   

GG

17 [29.82]

40 [70.18]

 

GT

29 [34.52]

55 [65.48]

 

TT

13 [33.33]

26 [66.67]

0.841

CYP2B6*18,

   

TT

43 [32.58]

89 [67.42]

 

TC

14 [29.79]

33 [70.21]

 

CC

3 [50.00]

3 [50.00]

0.608

CYP2A6*9,

   

GG

33 [30.00]

77 [70.00]

 

TT

8 [33.33]

16 [66.67]

0.748

CYP2A6*17,

   

GG

38 [31.67]

82 [68.33]

 

GA

3 [20.00]

12 [80.00]

 

AA

1 [100]

0 [0]

0.212

ABCB1236 C/T

   

CC

37 [32.17]

78 [67.83]

 

CT

5 [31.25]

11 [68.75]

 

TT

0 [0]

6 [100]

0.316

  1. The distribution of study variable outcomes grouped by sex and presented as mean and standard deviation (SD) for continuous variables and total number and [%] for categorical variables.
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us